Hansoh Pharmaceutical says Risvutatug rezetecan enters NMPA priority review
Hansoh Pharmaceutical Group said its Risvutatug rezetecan injection has been included in China’s NMPA priority review.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.